UroGen Pharma Ltd (NAS:URGN) Stock News, Headlines & Updates
UroGen Pharma Ltd Stock News from GuruFocus
- 1
Aug 14, 2024
UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Business Wire • 8:00am
Aug 13, 2024
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
Business Wire • 8:00am
UroGen Pharma Ltd (URGN) Q2 2024 Earnings: EPS Misses Estimates at -$0.91, Revenue Falls Short at $21.8 Million
GuruFocus Research • 7:32am
Aug 05, 2024
UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
Business Wire • 8:00am
Jun 18, 2024
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Business Wire • 10:00pm
Jun 17, 2024
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
GlobeNewswire • 5:00pm
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
Marketwired • 4:00pm
Jun 13, 2024
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
Business Wire • 10:00am
Jun 07, 2024
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire • 8:00am
Jun 06, 2024
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
Business Wire • 8:00am
Jun 05, 2024
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
Business Wire • 8:00am
Jun 03, 2024
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
Business Wire • 8:00am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news